ArticleWorld journal of surgical oncology2026
Early recurrence prediction after curative-intent surgery of intrahepatic cholangiocarcinoma using a novel weighted tumor burden score.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecurrence after curative-intent resection of patients with intrahepatic cholangiocarcinoma (ICC) remains common and difficult to predict. Tumor burden scores (TBS) incorporating tumor size and tumor nodule number have been proposed, but the relative contribution of multifocality remains unclear.
methodsPatients undergoing curative-intent surgery for ICC in a large hepatobiliary center between 2009 and 2024 were retrospectively analyzed. A simplified weighted tumor burden score (wTBS) was developed using tumor size and tumor nodule number (wTBS = largest tumor diameter (cm) + 5 × tumor nodule number). The score was derived in a primary cohort and externally validated in an independent cohort. Early recurrence was defined as recurrence within 12 months after surgery. Predictive performance was assessed using logistic regression analysis, receiver operating characteristic (ROC) analysis, Kaplan-Meier survival curve analysis and Cox regression models.
resultsA total of 198 patients were included in this study. In the study cohort, the wTBS was significantly associated with early recurrence (OR 1.12 per point, 95% CI 1.07-1.18, p < 0.001) and recurrence-free survival (RFS; HR 1.06 per point, 95% CI 1.04-1.09, p < 0.001). ROC analysis demonstrated improved discriminatory performance compared to tumor size or tumor nodule number alone (area under the curve [AUC] 0.69). Using a cutoff of ≥ 14, patients with high wTBS had significantly shorter RFS (median 9 vs. 21 months, p < 0.001). These findings were confirmed in an independent validation cohort comprising 162 patients, in which wTBS remained significantly associated with early recurrence (OR 1.12) and RFS (HR 1.08, p < 0.001) with a median RFS of 7 vs. 26 months for high- vs. low-risk patients.
conclusionsA simplified wTBS incorporating tumor size and tumor nodule number was associated with early recurrence after ICC resection and showed consistent prognostic value in an independent cohort. Given its moderate discriminatory ability, the score should currently be regarded as an adjunct for postoperative risk stratification rather than a stand-alone tool for treatment selection. Prospective validation and evaluation of clinical utility are required before implementation in treatment algorithms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.